Arcarios focuses on the development of novel disease-modifying therapeutics in the field of bone and joint diseases. Its
products are aimed at actively restoring bone or joint defects and address a clear unmet medical need.
The Company has two early pre-clinical programs: a small molecule that will be developed for the treatment of osteoarthritis and a therapeutic protein, which will be developed to treat specific
bone diseases. In addition Arcarios has two high-content screening platforms: ChondroBOOST and OsteoBLAST that focus on the discovery of new drug-targets in the field of joint and bone diseases respectively.
Arcarios is headquartered in Rotterdam, The
Netherlands and has research facilities in Rotterdam and Diepenbeek (Belgium).